Company: SION
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-101830
Chunk: 50

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 50
---
, described below. |

| (2) | This amount is based on the fair market value of a share of our common stock equal to $10.33 as of December 31, 2024, as determined by our board of directors. |

| (3) | The shares underlying this restricted stock award vest over a four-year period as follows: 25% of such shares vested on the first anniversary of the vesting commencement date, and the remaining 75% of the shares vest in 36 equal monthly installments thereafter, in each case, subject to the NEO’s continuous “service relationship” (as defined in the 2020 Plan) with us through each applicable vesting date. Notwithstanding the foregoing, this award is subject to acceleration of vesting benefits as set forth in the NEO’s Severance and CIC Agreement and/or the New Severance and CIC Plan, as applicable. |

| (4) | The shares underlying this stock option award vest in 48 equal monthly installments over a four-year period following the vesting commencement date, in each case, subject to the NEO’s continuous “service relationship” (as defined in the 2020 Plan) with us through each applicable vesting date. Under the applicable award agreement, the shares underlying this option will become fully vested upon a sale event (as defined in the 2020 Plan). Notwithstanding the foregoing, this award is also subject to acceleration of vesting benefits as set forth in the NEO’s Severance and CIC Agreement and/or the New Severance and CIC Plan, as applicable. |

| (5) | The shares underlying this award vest over a four-year period as follows: 25% of such shares vested on the first anniversary of the vesting commencement date, and the remaining 75% of the shares vest in 36 equal monthly installments thereafter, in each case, subject to the NEO’s continuous “service relationship” (as defined in the 2020 Plan) with us through each applicable vesting date. Under the applicable award agreement, the shares underlying this award will become fully vested upon a sale event (as defined in the 2020 Plan) of our company. Notwithstanding the foregoing, this award is also subject to acceleration of vesting benefits as set forth in the NEO’s offer letter, the NEO’s Severance and CIC Agreement and/or the New Severance and CIC Plan, as applicable. For Dr. McKee’s restricted stock award only, such award is also subject to certain